Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs

Cardiovascular Research

Volumn 49, Issue 4, 2001, Pages 762-770

  Fareh, Samir ^a   Bénardeau, Agnès ^a,b   Nattel, Stanley ^a,c  

^a MONTREAL HEART INSTITUTE   (Canada)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Antiarrhythmic agents; Arrhythmia (mechanisms); Ca channel; Supraventr. arrhythmia

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL T TYPE; CALCIUM ION; DILTIAZEM; MIBEFRADIL; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM HOMEOSTASIS; CARDIOVERSION; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART ATRIUM REMODELING; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; TACHYCARDIA;

ANALYSIS OF VARIANCE; ANIMALS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; DILTIAZEM; DOGS; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HEART ATRIA; MIBEFRADIL; SINGLE-BLIND METHOD; STATISTICS, NONPARAMETRIC; TACHYCARDIA;

EID: 0035113546     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00288-1     Document Type: Article

References (42)

1. Epidemiology of atrial fibrillation
2. Epidemiologic features of chronic atrial fibrillation: The Framingham study
3. Newer developments in the management of atrial fibrillation
4. The molecular and ionic specificity of antiarrhythmic drug actions
5. Atrial electrophysiological remodeling caused by rapid atrial activation: Underlying mechanisms and clinical relevance to atrial fibrillation
6. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats
7. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation
8. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling
9. Electrical remodeling in atrial fibrillation. Time course and mechanisms
10. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model
11. Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced electrical remodeling
12. 2+ and cellular contractility
13. Effect of verapamil and procainamide on atrial-fibrillation-induced electrical remodeling in humans
14. Tachycardia-induced change of atrial refractory period in humans. Rate dependency and effects of antiarrhythmics drugs
15. Verapamil reduces tachycardia-induced electrical remodeling of the atria
16. Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644
17. Short-term effect of atrial fibrillation on atrial contractile function in humans
18. Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling
19. Early recurrences of atrial fibrillation after electrical cardioversion: A result of fibrillation-induced electrical remodeling of the atria?
20. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs
21. 2+ channels by Ro 40-5967
22. 2+ channels
23. 2+ channels and pharmacological blockade: Potential pathophysiological relevance
24. Effects of mibefradil, a T-type calcium current antagonist, on electrophysiology of Purkinje fibers that survived in the infarcted canine heart
25. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels
26. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation
27. Comparative study of the efficacy of T- and L-type calcium channel blockers against atrial remodeling due to sustained atrial tachycardia
28. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium
29. Steady-state dose proportionality of a once-a-day sustained-release diltiazem hydrochloride formulation in healthy subjects
30. Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation
31. Frequency-dependent effects of calcium antagonists on atrioventricular conduction and refractoriness: Demonstration and characterization in anesthetized dogs
32. Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation
33. Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model
34. Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation
35. Dihydropyridine and beta adrenergic receptor binding in dogs with tachycardia-induced atrial fibrillation
36. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: A single-blind, randomized, controlled study
37. What lessons can be learnt from withdrawal of mibefradil from the market?
38. Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists
39. Amiodarone to prevent recurrence of atrial fibrillation
40. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes
41. Ks
42. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro